Stockscreener 앱 받기
17.08
0.99%
-0.17
시장 영업 전:
17.07
-0.010
-0.06%
Personalis Inc 주식(PSNL)의 최신 뉴스
Tempus AI Shares Jump $3 Billion After Moderna Victory Boosts Value of $1.5 Billion Personalis Stake - TechStock²
AMERIPRISE FINANCIAL INC Trims Personalis Inc (PSNL) Stake -- Shares Trade 590% Above GF Value - GuruFocus
Why Tempus AI (TEM) Is Up 22.8% After Buying the Platform Behind a Key mRNA Cancer Win - simplywall.st
Deep Track Capital, LP Trims Personalis Inc (PSNL) Stake -- Shar - GuruFocus
Personalis secures new Million Veteran Program task order - TipRanks
Personalis Receives New Task Order Under U.S. Veterans Affairs Contract For VA MVP - TradingView
Personalis wins up to $18.3M VA MVP task order, cumulative VA awards reach $243.3M - TradingView
Personalis (NASDAQ: PSNL) wins Million Veteran Program task order—how big is it? - Stock Titan
TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight - Stocktwits
Tempus soars on coattails of Moderna/Merck cancer vaccine - Crain's Chicago Business
Personalis stock reaches 52-week high at 16.42 USD - Investing.com
Personalis stock reaches 52-week high at 16.42 USD By Investing.com - Investing.com Canada
Tempus AI Just Had Their Entire Strategy Validated By Moderna’s Vaccine Advance (TEM) - Seeking Alpha
Personalis | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Personalis Inc : PSNL - 247wallst.com
Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant - Yahoo Finance
Tempus AI Jumps 24% as Merck-Moderna mRNA Vaccine Win Lifts Personalis Deal - finance.biggo.com
TEM Stock Dips As Tempus AI Bets $1.5B On Personalis - StocksToTrade
Personalis Inc. (PSNL) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition - Benzinga
Tempus AI Stock Slides As $1.5B Personalis Bet Raises Stakes - timothysykes.com
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
What Personalis (PSNL)'s Rising Revenue But Deepening Losses Means For Shareholders - webull.com
Tempus Is Buying Cancer-Testing Partner Personalis for $1.5 Billion - RamaOnHealthcare
Ameriprise Financial (PSNL) discloses 5.8% ownership stake in Personalis common stock - Stock Titan
Deep Track Capital (PSNL) reports 4,000,000 Personalis shares, now under 5% ownership - Stock Titan
Sei Investments Co. Buys 83,040 Shares of Personalis, Inc. $PSNL - MarketBeat
Personalis, Inc. (PSNL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Personalis Inc (PSNL) Shares Fall 3.2% -- What GF Score of 53 Te - GuruFocus
Personalis, Inc. $PSNL Stock Holdings Lifted by Dimensional Fund Advisors LP - MarketBeat
Personalis (PSNL) Is Up 6.1% After Q2 Revenue Rises But Losses DeepenWhat's Changed - webull.com
TEM Surges Into $1.5B MRD Deal As Stock Pulls Back - StocksToTrade
Tempus AI Stock Drops As $1.5B Personalis Deal Ups The MRD Stakes - StocksToTrade
Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Personalis Inc (PSNL) Stock News Today - TradingKey
Cancer Detection Test Receives Regulatory Marking for Use in Great Britain - Clinical Lab Products
Growth Potential For Personalis, Inc. (PSNL): A Look At Its 30% Revenue Surge - DirectorsTalk Interviews
Personalis Inc (PSNL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lake Street Maintains Personalis(PSNL.US) With Hold Rating, Maintains Target Price $16.25 - Moomoo
Personalis Reports Second Quarter 2026 Results and Recent Highlights - biospace.com
Is Personalis Inc (PSNL) Significantly Overvalued Even After Q2 Revenue of $22.4 Million? GF Score: 59/100 - GuruFocus
Personalis : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Personalis (NASDAQ:PSNL) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Personalis, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Personalis, Inc. Q2 2026: Revenue $22.36M, EPS $(0.30) — 10-Q Summary - TradingView
Earnings Flash (PSNL) Personalis, Inc. Reports Q2 Revenue $22.4M, vs. FactSet Est of $16.7M - marketscreener.com
Personalis Q2 revenue rises 30% to $22.4 million - Quiver Quantitative
Personalis Q2 revenue rises 30%, beats estimates on expanded Medicare coverage - TradingView
Personalis (NASDAQ: PSNL) posts larger loss and strikes Tempus cash-stock merger - Stock Titan
Personalis: Q2 Earnings Snapshot - marketscreener.com
Personalis (NASDAQ: PSNL) Q2 revenue jumps 30% as clinical tests surge - stocktitan.net
Personalis Reports Second Quarter Results and Recent Highlights - marketscreener.com
PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AI - marketscreener.com
Swiss National Bank Invests $671,000 in Personalis, Inc. $PSNL - MarketBeat
How Investors May Respond To Tempus AI (TEM) Q2 Profit Return, Outlook Hike, Personalis Deal - Yahoo Finance
Tempus AI buys Personalis for $1.7B as digital health M&A su - MarketScale
TEM: Q2 revenue up 22% YoY, net income positive, and Personalis acquisition announced - TradingView
BlackRock (PSNL holder) discloses 5.9% beneficial stake in Personalis common stock - Stock Titan
PSNL|Personalis Inc|Price:11.989|Chg%:+0.209 - TradingKey
Personalis Inc (PSNL) Valuation: PE, PB & Fair Value Analysis - TradingKey
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - globenewswire.com
Tempus AI Stock (TEM) Opinions on Personalis Acquisition and Analyst Upgrades - Quiver Quantitative
Tempus AI to Acquire Personalis in $1.5 Billion Deal, Deepening Its Foothold in Cancer Monitoring - Oncodaily
Personalis Inc (PSNL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
0.58%
0.81%
자본화:
|
볼륨(24시간):